Who makes Plavix® and PA32540?

Plavix® and PA32540 is developed by POZEN.

What development phase is Plavix® and PA32540 in?

Plavix® and PA32540 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Plavix® and PA32540

POZEN · Phase 1 active Small molecule

At a glance

Generic name	Plavix® and PA32540
Sponsor	POZEN
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Plavix® and PA32540 CI brief — competitive landscape report
Plavix® and PA32540 updates RSS · CI watch RSS
POZEN portfolio CI